Bioject Announces National Institutes of Health Begins Human Ebola Vaccine Trial Utilizing Biojector 2000
BEDMINSTER, N.J. -- Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, announced today that the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, recently began its first human trial of a vaccine to prevent Ebola infection utilizing the Biojector 2000 (B-2000). The B-2000 is a needle-free injection system that is powered by a compressed gas system and is the only device being utilized in the study.
Earlier this year, Bioject had entered into a services and supply subcontract with SAIC-Frederick, Inc., a subsidiary of Science Applications International Corporation-Frederick (SAIC-Frederick) under its contract with the National Cancer Institute, Frederick, where by Bioject will supply the VRC/NIAID, with the non-exclusive right to utilize Bioject's B-2000 needle- free injection systems in VRC-sponsored clinical trials for experimental vaccines against HIV and Ebola. The HIV human clinical trials are currently underway.
Bioject Medical Technologies Inc., is an innovative developer and manufacturer of needle-free drug delivery systems and vial adapter products. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
Source: Bioject Medical Technologies Inc.
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
